论文部分内容阅读
目的:观察热毒宁联合莫西沙星治疗风热犯肺型社区获得性肺炎的临床疗效。方法:选取64例风热犯肺型社区获得性肺炎患者,随机分为治疗组和对照组各32例,治疗组给予热毒宁联合莫西沙星治疗,对照组仅给予莫西沙星治疗。观察两组总有效率、临床症状、白细胞、中性粒细胞、CRP、退热时间及不良反应等情况。结果:总有效率治疗组为90.62%,对照组为78.12%,组间比较,差异均有统计学意义(均P<0.05);治疗后退热时间、临床症状积分、CRP组间比较,差异均有统计学意义(均P<0.05)。结论:热毒宁联合莫西沙星治疗风热犯肺型社区获得性肺炎疗效优于单用莫西沙星治疗。
OBJECTIVE: To observe the clinical efficacy of combination of Minuduxin and moxifloxacin in the treatment of community-acquired pneumonia with wind-heat syndrome. Methods: Sixty-four patients with wind-induced fever-causing pulmonary community-acquired pneumonia were randomly divided into treatment group (32 cases) and control group (32 cases). The treatment group was treated with Rendoxine combined with moxifloxacin, while the control group was given moxifloxacin alone. The total effective rate, clinical symptoms, white blood cells, neutrophils, CRP, antipyretic time and adverse reactions in both groups were observed. Results: The total effective rate was 90.62% in the treatment group and 78.12% in the control group. There was significant difference between the two groups (all P <0.05). After treatment, the antipyretic time, clinical symptom scores, There was statistical significance (all P <0.05). CONCLUSION: The combination of Rendoxin and Moxifloxacin is superior to moxifloxacin alone in the treatment of wind-heat syndrome-causing pulmonary community-acquired pneumonia.